Nalpropion Drug Patent Portfolio
Nalpropion owns 1 orange book drug protected by 22 US patents Given below is the list of Nalpropion's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10231964 | Compositions and methods for weight loss in at risk patient populations | 02 Jul, 2034 | Active |
| US10828294 | Compositions and methods for weight loss in at risk patient populations | 02 Jul, 2034 | Active |
| US10835527 | Compositions and methods for reducing major adverse cardiovascular events | 02 Jul, 2034 | Active |
| US11998542 | Compositions and methods for reducing major adverse cardiovascular events | 02 Jul, 2034 | Active |
| US9633575 | Methods of treating overweight and obesity | 25 Jun, 2033 | Active |
| US10403170 | Methods of treating overweight and obesity | 05 Jun, 2033 | Active |
| US11139056 | Methods of treating overweight and obesity | 05 Jun, 2033 | Active |
| US9248123 | Methods of providing weight loss therapy in patients with major depression | 13 Jan, 2032 | Active |
| US11033543 | Methods of providing weight loss therapy in patients with major depression | 10 Jan, 2031 | Active |
| US8916195 | Sustained release formulation of naltrexone | 02 Feb, 2030 | Active |
| US11324741 | Methods for treating visceral fat conditions | 29 May, 2029 | Active |
| US8088786 | Layered pharmaceutical formulations | 03 Feb, 2029 | Active |
| US10307376 | Methods for administering weight loss medications | 08 Nov, 2027 | Active |
| US12048769 | Methods for administering weight loss medications | 08 Nov, 2027 | Active |
| US8318788 | Layered pharmaceutical formulations | 08 Nov, 2027 | Active |
| US8722085 | Methods for administering weight loss medications | 08 Nov, 2027 | Active |
| US9125868 | Methods for administering weight loss medications | 08 Nov, 2027 | Active |
| US9107837 | Sustained release formulation of naltrexone | 04 Jun, 2027 | Active |
| US7375111 | Compositions for affecting weight loss | 26 Mar, 2025 | Expired |
| US7462626 | Compositions for affecting weight loss | 20 Jul, 2024 | Expired |
| US8815889 | Compositions and methods for increasing insulin sensitivity | 20 Jul, 2024 | Expired |
| US11278544 | Compositions for affecting weight loss | 21 Apr, 2024 | Expired |
Latest Legal Activities on Nalpropion's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nalpropion.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 19 Mar, 2025 | US11139056 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 27 Nov, 2024 | US11033543 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 09 Oct, 2024 | US9633575 |
| Recordation of Patent Grant Mailed | 30 Jul, 2024 | US12048769 |
| Patent Issue Date Used in PTA Calculation | 30 Jul, 2024 | US12048769 |
| Recordation of Patent eGrant | 30 Jul, 2024 | US12048769 |
| Patent eGrant Notification | 30 Jul, 2024 | US12048769 |
| Email Notification | 30 Jul, 2024 | US12048769 |
| Mail Patent eGrant Notification | 30 Jul, 2024 | US12048769 |
| Electronic Review | 30 Jul, 2024 | US12048769 |
| Email Notification | 11 Jul, 2024 | US12048769 |
| Issue Notification Mailed | 10 Jul, 2024 | US12048769 |
| Application Is Considered Ready for Issue | 27 Jun, 2024 | US12048769 |
| Dispatch to FDC | 27 Jun, 2024 | US12048769 |
| Issue Fee Payment Received | 25 Jun, 2024 | US12048769 |
Nalpropion's Family Patents
Nalpropion drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 27.3% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Nalpropion Drug List
Given below is the complete list of Nalpropion's drugs and the patents protecting them.
1. Contrave
Contrave is protected by 22 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10231964 | Compositions and methods for weight loss in at risk patient populations |
02 Jul, 2034
(8 years from now)
| Active |
| US10828294 | Compositions and methods for weight loss in at risk patient populations |
02 Jul, 2034
(8 years from now)
| Active |
| US10835527 | Compositions and methods for reducing major adverse cardiovascular events |
02 Jul, 2034
(8 years from now)
| Active |
| US11998542 | Compositions and methods for reducing major adverse cardiovascular events |
02 Jul, 2034
(8 years from now)
| Active |
| US9633575 | Methods of treating overweight and obesity |
25 Jun, 2033
(7 years from now)
| Active |
| US10403170 | Methods of treating overweight and obesity |
05 Jun, 2033
(7 years from now)
| Active |
| US11139056 | Methods of treating overweight and obesity |
05 Jun, 2033
(7 years from now)
| Active |
| US9248123 | Methods of providing weight loss therapy in patients with major depression |
13 Jan, 2032
(5 years from now)
| Active |
| US11033543 | Methods of providing weight loss therapy in patients with major depression |
10 Jan, 2031
(4 years from now)
| Active |
| US8916195 | Sustained release formulation of naltrexone |
02 Feb, 2030
(3 years from now)
| Active |
| US11324741 | Methods for treating visceral fat conditions |
29 May, 2029
(3 years from now)
| Active |
| US8088786 | Layered pharmaceutical formulations |
03 Feb, 2029
(2 years from now)
| Active |
| US10307376 | Methods for administering weight loss medications |
08 Nov, 2027
(1 year, 7 months from now)
| Active |
| US12048769 | Methods for administering weight loss medications |
08 Nov, 2027
(1 year, 7 months from now)
| Active |
| US8318788 | Layered pharmaceutical formulations |
08 Nov, 2027
(1 year, 7 months from now)
| Active |
| US8722085 | Methods for administering weight loss medications |
08 Nov, 2027
(1 year, 7 months from now)
| Active |
| US9125868 | Methods for administering weight loss medications |
08 Nov, 2027
(1 year, 7 months from now)
| Active |
| US9107837 | Sustained release formulation of naltrexone |
04 Jun, 2027
(1 year, 2 months from now)
| Active |
| US7375111 | Compositions for affecting weight loss |
26 Mar, 2025
(11 months ago)
| Expired |
| US7462626 | Compositions for affecting weight loss |
20 Jul, 2024
(1 year, 7 months ago)
| Expired |
| US8815889 | Compositions and methods for increasing insulin sensitivity |
20 Jul, 2024
(1 year, 7 months ago)
| Expired |
| US11278544 | Compositions for affecting weight loss |
21 Apr, 2024
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Contrave's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List